SLC5A2 and heart failure: Empagliflozin and other SGLT2 inhibitors have significantly lowered the incidence of heart failure-related hospitalization and cardiovascular death in people with type-2 diabetes, as demonstrated by trials like EMPA-REG OUTCOME, even in individuals without prior heart failure.